Enzychem Lifesciences   Report issue

For profit Phase 2
Founded: Seoul Korea, Republic of (1999)

Organization Overview

First Clinical Trial
2015
NCT02532712
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Enzychem Lifesciences Corporation

Active Ingredients

Drugs in Phase 2 Trials (1)

ec-18 (7 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Febrile Neutropenia (Phase 2)

Fever (Phase 2)

Mucositis (Phase 2)

Neutropenia (Phase 2)

Pneumonia (Phase 2)

Stomatitis (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 7
  • # of Trial APIs: 1